MONTREAL, Feb. 28, 2013 /CNW Telbec/ - BIOQuébec is pleased to announce the
appointment of Dr. Martin Godbout as chairman of the Board, replacing Mr.
Gilles R. Gagnon, who held this position during the last 2 years. Mr.
Godbout's appointment comes into force today.
"Since its creation, BIOQuébec has played a key role as spokesperson of the
biotechnology industry. It is with humility that I accept to collaborate, with
all members of the Board, towards the development of strategies that will
further the industry and promote the life sciences sector not only in Québec
but abroad", stated Dr. Godbout.
As director on BIOQuébec's Board for the last 2 years, Dr. Godbout also sits
on several other Boards of biotechnology companies, foundations and Canadian
scientific organizations. He is president of the MethylGene inc. and Génome
Québec Boards and acts as director on the Boards of the following
organizations: Acasti Pharma Inc., AmorChem Inc., AngioChem Inc., AsmaCure
Inc., BioContact, the Fonds de recherche du Québec - santé (FQRS), Montréal
In Vivo and the Fondation de l'Ataxie de Charlevoix.
Dr. Godbout founded Génome Canada, and was its president and CEO for many
years. Throughout his career, he sat on the Science and Technology Council of
Québec and was a member of the Natural Sciences and Engineering Research
Council of Canada. He also developed BioContact Québec, an annual symposium
on biopharmaceutical partnerships. He held the position of senior
vice-president of BioCapital, a major Canadian venture capital firm. Prior to
this, he was CEO of Société Innovatech Québec, a technology investment
fund. Dr. Godbout is an Officer of the Order of Canada and has received
numerous awards in Canada and abroad.
BIOQuébec's Board of Directors would like to thank Mr. Gagnon for his
contribution to the association and wishes him much luck in his future
BIOQuébec is a biotechnology and life science industry association
representing nearly 100 member companies and R&D centres in Québec. The
association works to create a positive business environment which fosters the
growth of the life science industry, including access to capital and access to
development and marketing partners, workforce development, a regulatory and
competitive tax environment and the promotion of its members among various
publics both in Québec and on an international level.
Board of Directors 2012-2013
-- Dr. Martin Godbout
President of the Board
Hodran Consultants Inc.
-- Mario Lebrun
-- Michel Fortin
Prevtec microbia inc.
-- John-Michel T. Huss
-- Yves Roy
Corealis Pharma Inc.
-- Andy Sheldon
-- Cédric Bisson
Teralys Capital Inc.
-- Jean-Paul Castaigne
-- Richard Cherney
Davies Ward Phillips & Vineberg, s.r.l.
-- Claude Chevalier
BIO-K + International Inc.
-- Pierre Falardeau
Oncozyme Pharma Inc.
-- Jean Godin
Chief Scientific Officer
Novartis Pharma Canada Inc.
-- Charles Grubsztajn
-- Dr. Pavel Hamet
-- Grant Perry
Vice-President, Public Affairs and Reimbursement
-- Louise Proulx
Mario Lebrun BIOQuébec General Manager 450-781-3965 email@example.com
To view this news release in HTML formatting, please use the following URL:
NI: BTC 2575 WNEWS
-0- Feb/28/2013 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.